Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT01522976 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

282

Enrollment

NIH

Sponsor class

Conditions

Chronic Myelomonocytic Leukemia
Chronic Myelomonocytic Leukemia-1
Chronic Myelomonocytic Leukemia-2
Myelodysplastic Syndrome
Myelodysplastic Syndrome With Excess Blasts
Myelodysplastic Syndrome With Excess Blasts-1
Myelodysplastic Syndrome/Acute Myeloid Leukemia

Interventions

DRUG: Azacitidine
OTHER: Laboratory Biomarker Analysis
DRUG: Lenalidomide
DRUG: Vorinostat

Sponsor

National Cancer Institute (NCI)